Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
May 06, 2024 at 04:05 pm EDT
Share
Enanta Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported sales was USD 17.05 million compared to USD 17.8 million a year ago. Net loss was USD 31.16 million compared to USD 37.66 million a year ago. Basic loss per share from continuing operations was USD 1.47 compared to USD 1.79 a year ago. Diluted loss per share from continuing operations was USD 1.47 compared to USD 1.79 a year ago.
For the six months, sales was USD 35.06 million compared to USD 41.38 million a year ago. Net loss was USD 64.56 million compared to USD 66.64 million a year ago. Basic loss per share from continuing operations was USD 3.06 compared to USD 3.19 a year ago. Diluted loss per share from continuing operations was USD 3.06 compared to USD 3.19 a year ago.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).
ENANTA PHARMACEUTICALS, INC. 
